Key result
Breast cancer radiotherapy yields low overall cardiac exposure with ~0.6 Gy median heart dose.
Why the study?
Radiotherapy for early breast cancer is associated with long-term cardiovascular morbidity, and understanding dose to cardiac substructures and temporal trends is essential for optimizing cardiac risk.
What is the contemporary radiation dose exposure to the heart and cardiac substructures in early breast cancer patients receiving adjuvant radiotherapy, and how has it changed over time?
Observational (n=6,926)
No
What is the contemporary radiation dose exposure to the heart and cardiac substructures in early breast cancer patients receiving adjuvant radiotherapy, and how has it changed over time?
p-value: p=<0.001
Contemporary adjuvant radiotherapy for early breast cancer results in very low cardiac doses for most patients, though mean heart and left anterior descending coronary artery doses have increased over time for left-sided locoregional treatments due to changing planning priorities.
May warrant refined cardiac sparing for left-sided locoregional RT; leaves open substructure-specific cardiotoxicity risks in modern cohorts.
Background/Introduction Radiotherapy (RT) for early breast cancer (eBC) has been associated with increased long-term cardiovascular morbidity, primarily due to cardiac irradiation. Although advances in RT planning have substantially reduced mean heart dose (MHD), evidence suggests that dose to specific cardiac substructures may be more relevant for radiation-induced cardiotoxicity. Understanding contemporary cardiac and substructure dose exposure, as well as temporal trends, is essential for optimizing cardiac risk among cancer patients. Purpose The purpose is to quantify radiation dose to the heart and cardiac substructures in eBC patients treated with adjuvant RT and to evaluate changes in cardiac dose exposure over time in a real-world clinical cohort. Methods All eBC patients receiving adjuvant RT at a single institution between 2009 and 2020 were included. Planning CT scans were retrieved, and the heart and nine cardiac substructures were automatically delineated using the open-source AI-based tool PlatiPy. A random 10% of delineations underwent manual validation and were accepted without modification. Dose metrics were extracted from the treatment planning system and reported as EQD2 (α/β = 2 Gy). Temporal changes in cardiac and substructure dose exposure were assessed using Wilcoxon tests. Results In total, 6926 patients were included (3562 left-sided eBC patients and 3364 right-sided eBC patients). RT planning and delivery varied over time; deep inspiration breath-hold was available throughout the study period, and 3D-conformal RT was the predominant technique. Figure 1 shows mean dose to the heart and 9 cardiac substructures. Changes in median mean doses over time are illustrated in Figure 2. Median MHD for the entire cohort was 0.57 Gy (IQR: 0.29–0.99). For left-sided locoregional RT, MHD increased significantly over time (p < 0.001), whereas a significant decrease was observed for right-sided breast-only RT (p < 0.0001). Dose exposure to cardiac substructures was generally low. The highest median doses were observed for the left anterior descending coronary artery (LAD) during left-sided locoregional RT (2.70 Gy, IQR: 2.12–4.77) and for the right coronary artery (RCA) during right-sided locoregional RT (1.45 Gy, IQR: 1.16–2.00). Median LAD dose increased significantly over time for left-sided locoregional RT (p < 0.01), but not for left-sided breast-only RT (p = 0.19). These results likely reflect multiple factors, including the DBCG IMN study [2], which increased IMN-cover-age prioritization from 2015 and a shift toward a MHD rather than a LAD dose guidance in 2017. Conclusions Contemporary adjuvant RT for eBC results in very low cardiac and substructure doses for most patients. However, a significant increase in MHD and LAD dose over time was observed for left-sided locoregional RT due to changes in planning priorities. Further investigations include linkage of dosimetry data to cardiotoxicity outcomes.
No takes yet. Share an insight, caveat, or question.
Irankunda et al. (2026) conducted an observational in Early breast cancer (n=6,926). Adjuvant radiotherapy was evaluated on Mean heart dose (MHD) and cardiac substructure doses (p=<0.001). Adjuvant radiotherapy for early breast cancer resulted in low overall mean heart dose (median 0.57 Gy), though doses increased significantly over time for left-sided locoregional radiotherapy (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: